Plant Name: Rauvolfia serpentina
Taxonomic Information:
Plant ID: NPO7282
Plant Latin Name: Rauvolfia serpentina
Taxonomy Genus: Rauvolfia
Taxonomy Family: Apocynaceae
Plant External Links:
NCBI TaxonomyDB:
4060
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
Thailand; Indonesia; India; VietnamTraditional Medicine System:
Sowa-Rigpa; Indian Folk; Unani; Siddha; Ayurveda; HomeopathyGeographical Distribution:
Thailand; Indonesia; India; Vietnam
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADRA2C; ADRA2A; ADRA2B; ADRA1B; HTR2B; ADORA3; | |
| PDE10A; | |
| PDE3A; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Phosphodiesterase 10 | PDE10A | Phosphodiesterase 10A | Q9Y233 | CHEMBL4409 |
| Phosphodiesterase 3 | PDE3A | Phosphodiesterase 3A | Q14432 | CHEMBL241 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Small molecule receptor (family A GPCR) | ADRA1B | Alpha-1b adrenergic receptor | P35368 | CHEMBL232 |
| Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.374E-10 | 5.983E-07 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 2.745E-10 | 9.960E-07 | ADRA1B, ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 5.494E-10 | 1.309E-06 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 5.494E-10 | 1.309E-06 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 7.682E-09 | 7.965E-06 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 7.682E-09 | 7.965E-06 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 8.143E-07 | 4.925E-04 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.417E-06 | 2.046E-03 | CYP2C19, CYP2D6 |
| BP | GO:0009987; cellular process | GO:0043410; positive regulation of MAPK cascade | 5.145E-06 | 2.334E-03 | ADRA1B, ADRA2A, ADRA2B, ADRA2C, HTR2B |
| BP | GO:0009987; cellular process | GO:0007200; phospholipase C-activating G-protein coupled receptor signaling pathway | 1.419E-05 | 5.721E-03 | ADRA1B, ADRA2A, HTR2B |
| BP | GO:0008152; metabolic process | GO:0006198; cAMP catabolic process | 2.673E-05 | 9.486E-03 | PDE10A, PDE3A |
| MF | GO:0003824; catalytic activity | GO:0047555; 3',5'-cyclic-GMP phosphodiesterase activity | 2.673E-05 | 9.486E-03 | PDE10A, PDE3A |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 2.868E-05 | 9.913E-03 | ADRA2A, ADRA2B, ADRA2C |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 1.382E-10 | 3.318E-09 | ADORA3, PDE3A, ADRA2C, ADRA1B, ADRA2B, ADRA2A |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 2.915E-09 | 3.498E-08 | ADORA3, HTR2B, ADRA2C, ADRA1B, ADRA2B, ADRA2A |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 2.730E-05 | 2.184E-04 | CYP2D6, HTR2B, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 6.323E-04 | 3.794E-03 | CYP2D6, CYP2C19 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05032 | Morphine addiction | 1.097E-03 | 5.263E-03 | PDE10A, PDE3A |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | ADRA1B; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRA2C; |
| I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; ADORA3; |
| NA: NA | Schizoaffective disorder | NA | PDE10A; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | PDE10A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; HTR2B; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA1B; ADRA2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA2A; ADRA2C; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HTR2B; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; ADRA2C; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA1B; ADRA2C; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C; |
| I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Exogenous obesity | E66 | ADRA1B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | PDE10A; |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | HTR2B; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ADORA3; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C; HTR2B; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C; |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | HTR2B; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
